Companies Attending the Summit:
Fostering Collaboration Across Vietnam, China, Singapore, Taiwan, India and Australia to Advance APAC Cell Therapy Drug Development
Welcome to the 3rd CAR-TCR: Cell Therapy Summit Asia
In the dynamic landscape of cell therapy development, Asia is emerging as a powerhouse, witnessing a remarkable surge in investment and receiving strong regulatory support as companies rapidly progress in clinical and commercial development. Against this backdrop of rapid progress, the 3rd CAR-TCR: Cell Therapy Summit Asia stands as the pivotal gathering for industry players across the APAC region looking to capitalize on Asia's cell therapy boom.
Our Primary Focus This Year…
Deep dive into the evolving regulatory space across Asia to advance next-generation cell therapies to the clinic
Discover optimizing manufacturing processes to reduce costs of goods
Uncover how to reignite investment interest across Southeast Asia
Identify the best practice to streamline your commercial access to safer cell therapies
Must-Attend Sessions
Developing robust strategies to attract investments, forecast supply and demand and explore patient access for successful cell therapy commercialization and market access
Discovering best practices to achieve regulatory approvals and the importance of fostering collaborations in the community to boost cutting-edge cancer treatments
Latest Phase 1 Autoimmune clinical trial data using CD19 CAR-T to treat SLE patients, focusing on safety, tolerability, and determining the recommended Phase 2 dose
2024 Expert Speakers
Penceramah
专家发言人
Francesca Lim
Chief Medical Officer, Senior Consultant, Deputy Head & Assistant Medical Director
Singapore General Hospital, Singhealth, HSA & ACTRIS
About CAR-TCR Series
For over nine years, the CAR-TCR Summit Series by Hanson Wade has stood as a pillar of knowledge-sharing in the field of cell therapy. The series is committed to delivering an exclusive platform to unite the community and explore the key challenges to your industry, guided by global thought leaders in each discipline.
Dedicated to the development of safe, clinically effective and globally accessible therapies, the series is an unrivalled opportunity to gather with other cell therapy experts.
From next-generation development to supply chain and logistics, and exploring challenges specific to each function and indication, we create these forums to deliver value and in-depth learnings across the development pipeline, on a global stage.
